Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623481 | 0.91 | MAPT (0.36) | CCR3SCN9AMAPTACACBTP53 | |
| SCHEMBL6702187 | 0.87 | CCR3 (0.42) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6622074 | 0.84 | SCN9A (0.37) | CCR3SCN9AMAPTACACBTP53 | |
| SCHEMBL6620915 | 0.79 | CYP3A4 (0.43) | CCR3MAPTACACB | |
| SCHEMBL6623992 | 0.76 | MAPK1 (0.38) | MAPT | |
| SCHEMBL5762925 | 0.75 | MAPT (0.36) | MAPTTP53 | |
| SCHEMBL5761023 | 0.75 | MAPT (0.38) | MAPTHTR2ATP53 | |
| SCHEMBL5762210 | 0.74 | MAPT (0.35) | MAPTTP53 | |
| SCHEMBL6620293 | 0.73 | CNR1 (0.49) | CCR3MAPT | |
| SCHEMBL5333712 | 0.72 | MAPT (0.36) | MAPTACACBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |